Dyslipidemia and schizophrenia;Dyslipidämie bei langjähriger neuroleptischer behandlung

Psychiatrische Praxis

Volumn 34, Issue 5, 2007, Pages 223-229

  Wetterling, Tilman ^a,b   Schneider, Barbara ^a   Weber, Bernhard ^a  

^a GOETHE UNIVERSITY   (Germany)

^b Vivantes Klinikum Hellersdorf   (Germany)

Author keywords

Cholesterol; Dyslipidemia; Neuroleptics; Schizophrenia; Triglycerides

Indexed keywords

AMISULPRIDE; ATYPICAL ANTIPSYCHOTIC AGENT; BENPERIDOL; BROMPERIDOL; CHLORPROTHIXENE; CHOLESTEROL; CLOPENTHIXOL; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; HALOPERIDOL; LEVOMEPROMAZINE; MELPERONE; OLANZAPINE; PERAZINE; PERPHENAZINE; PIMOZIDE; PIPAMPERONE; PROMETHAZINE; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TRIACYLGLYCEROL; ZOTEPINE;

ADULT; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; CHRONIC DISEASE; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG EFFECT; DYSLIPIDEMIA; FEMALE; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; RISK FACTOR; SCHIZOPHRENIA; SIDE EFFECT; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTIPSYCHOTIC AGENTS; CHOLESTEROL; CHRONIC DISEASE; FEMALE; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; RISK FACTORS; SCHIZOPHRENIA; TRIGLYCERIDES;

EID: 34447525657     PISSN: 03034259     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-940056     Document Type: Article

References (37)

1. Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70: 1-17
2. Wetterling T. Hyperlipidämie - Nebenwirkung von "atypischen" Neuroleptika? Fortschr Neurol Psychiatr 2003; 71: 535-540
3. Atmaca M, Kuloglu M, Tezcan E, Gecici O, Ustundag B. Weight gain, serum leptin and triglyceride levels in patients with schizophrenia on antipsychotic treatment with quetiapine, olanzapine and haloperidol. Schizophr Res 2003; 60: 99-100
4. Gaulin BD, Markowitz JS, Caley CF, Nesbitt LA, Dufresne RL. Clozapine-associated elevation in serum triglycerides. Am J Psychiatry 1999; 156: 1270-1272
5. Koro CE, Fedder DO, L'Italien GJ, Weiss S, Magder LS, Kreyenbuhl J, Revicki D, Buchanan RW. An assessment of the independent effects of olanzapine and risperidone exposure on the risk of hyperlipidemia in schizophrenic patients. Arch Gen Psychiatry 2002; 59: 1021-1026
6. Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry 2002; 63: 856-865
7. Almeras N, Despres JP, Villeneuve J, Demers MF, Roy MA, Cadrin C, Mottard JP, Bouchard RH. Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. J Clin Psychiatry 2004; 65: 557-564
8. Lambert BL, Chang KY, Tafesse E, Carson W. Association between antipsychotic treatment and hyperlipidemia among California Medicaid patients with schizophrenia. J Clin Psychopharmacol 2005; 25: 12-18
9. Lindenmayer JP, Czobor P, Volavka J, Citrome L, Sheitman B, McEvoy JP, Cooper TB, Chakos M, Lieberman JA. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. Am J Psychiatry 2003; 160: 290-296
10. McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, Archibald D, Carson WH. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004; 65, Suppl 18: 47-56
11. Meyer JM. A rectrospective comparison of weight, lipid, and glucose changes between olanzapine- and risperidone-treated inpatients: metabolic outcomes after 1 year. J Clin Psychiatry 2002; 63: 425-433
12. Simpson CM, Glick ID, Weiden PJ, Romano SJ, Siu CO. Randomized, controlled, double-blind multicenter comparison of the efficacy and tolerability of ziprasidone and olanzapine in acutely ill inpatients with schizophrenia or schizoaffective disorder. Am J Psychiatry 2004; 161: 1837-1847
13. Gupta S, Steinmeyer C, Frank B, Madhusoodanan S, Lockwood K, Lentz B, Keller P. Hyperglycemia and hypertriglyceridemia in real world patients on antipsychotic therapy. Am J Ther 2003; 10: 348-355
14. Wittchen H-U, Glaesmer H, März W, Stalla G, Lehnert H, Zeiher AM, Silber S, Koch U, Böhler S, Pittrow D, Ruf G for the DETECT-Study Group. Cardiovascular risk factor in primarycare: methods and baseline prevalence rates - the DETECT program. Curr Med Res Opin 2005; 21: 619-629
15. Laaser U. Nutzen und Kosten bei Früherkennung und Frühbehandlung der Hypercholesterinämie. Z Kardiol 1994; 83, Suppl 6: 163-167
16. Richter WO, Richter V, Rassoul F, Sonnichsen AC, Rotzsch W, Schwandt P. Kardiovaskuläre Risikofaktoren in den alten und neuen Bundesländern. Fortschr Med 1993; 111: 214-218
17. Spelsberg A, Weiland K, Stolpe S, Segerling M, Keil U. Bochumer Cholesterin und Blutdruckscreening-Studie 1990. Fortschr Med 1992; 110: 387-392
18. Assmann G, Schulte H. The importance of triglycerides: results from the Prospective Cardiovascular Munster (PROCAM) Study. Eur J Epidemiol 1992; 8, Suppl 1: 99-103
19. Richter V, Rassoul F, Hentschel B, Kothe K, Krobara M, Unger R, Purschwitz K, Rotzsch W, Thiery J, Muradian K. Age-dependence of lipid parameters in the general population and vegetarians. Z Gerontol Geriatr 2004; 37: 207-213
20. Saari K, Koponen H, Laitinen J, Jokelainen J, Lauren L, Isohanni M, Lindeman S. Hyperlipidemia in persons using antipsychotic medication: a general population-based birth cohort study. J Clin Psychiatry 2004; 65: 547-550
21. Lund BC, Perry PJ, Brooks JM, Arndt S. Clozapine use in patients with schizophrenia and the risk of diabetes, hyperlipidemia, and hypertension: a claims-based approach. Arch Gen Psychiatry 2001; 58: 1172-1176
22. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999; 60: 767-770
23. Meyer JM. Novel antipsychotics and severe hyperlipidemia. J Clin Psychopharmacol 2001; 21: 369-374
24. Henderson DC, Cagliero E, Gray C, Nasrallah RA, Hayden DL, Schoenfeld DA, Goff DC. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: A five-year naturalistic study. Am J Psychiatry 2000; 157: 975-981
25. Henderson DC, Nguyen DD, Copeland PM, Hayden DL, Borba CP, Louie PM, Freudenreich O, Evins AE, Cather C, Goff DC. Clozapine, Diabetes Mellitus, Hyperlipidemia, and Cardiovascular Risks and Mortality: Results of a 10-Year Naturalistic Study. J Clin Psychiatry 2000; 66: 1116-1121
26. International Diabetes Federation. The IDF consensus worldwide definition of the metabolic syndrome. 2005, www.idf.org
27. Dilling H, Mombour W, Schmidt MH. Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V (F) Klinisch-diagnostische Leitlinien. 4. Aufl, Bern: Huber, 2000
28. Brown S, Inskip H, Barraclough B. Causes of the excess mortality of schizophrenia. Br J Psychiatry 2000; 177: 212-217
29. Joukamaa M, Heliovaara M, Knekt P, Aromaa A, Raitasalo R, Lehtinen V. Mental disorders and cause-specific mortality. Br J Psychiatry 2001; 179: 498-502
30. Palmer BA, Pankratz VS, Bostwick JM. The lifetime risk of suicide in schizophrenia: a reexamination. Arch Gen Psychiatry 2005; 62: 247-253
31. Curkendall SM, Mo J, Glasser DB, Rose Stang M, Jones JK. Cardiovascular disease in patients with schizophrenia in Saskatchewan, Canada. J Clin Psychiatry 2004; 65: 715-720
32. Enger C, Weatherby L, Reynolds RF, Glasser DB, Walker AM. Serious cardiovascular events and mortality among patients with schizophrenia. J Nerv Ment Dis 2004; 192: 19-27
33. Casey DE, Haupt DW, Newcomer JW, Henderson DC, Sernyak MJ, Davidson M, Lindenmayer JP, Manoukian SV, Banerji MA, Lebovitz HE, Hennekens CH. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry 2004; 65, Suppl 7: 4-18
34. Wetterling T. Hyperlipidämienebenwirkung bei Behandlung mit einem atypischen Neuroleptikum (Zotepin)? Psychiat Prax 2002; 29: 438-440
35. Baymiller SP, McMahon RP, Buchanan RW. Serum glucose and lipid changes during the course of clozapine treatment: the effect of concurrent beta-adrenergic antagonist treatment. Schizophr Res 2003; 59: 49-57
36. Consensus Development. Conference on Antipsychotic Drugs and Obesity and Diabetes. J Clin Psychiatry 2004; 65: 265-272
37. Marder SR, Essock SM, Miller AL, Buchanan RW, Casey DE, Davis JM, Kane JM, Lieberman JA, Schooler NR, Covell N, Stroup S, Weissman EM, Wirshing DA, Hall CS, Pogach L, Pi-Sunyer X, Bigger JT Jr, Friedman A, Kleinberg D, Yevich SJ, Davis B, Shon S. Physical health monitoring of patients in schizophrenia. Am J Psychiatry 2004; 161: 1334-1349